TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04140383

Intervention type: PROCEDURE
Intervention: Cataract Surgery
Description: Cataract surgery was performed by using phacoemulsification technique, routinely. But other techniques for instance extra or intracapsular cataract extraction (ECCE, ICCE) techniques were performed when needed. Phacoemulsification technique was performed by 2 experienced surgeon (G.A. and E.C.) under topical anesthesia, thorough limbal incision. Foldable single piece hydrophobic acrylic intraocular lens (IOL) was inserted in the bag. In the presence of complications related to anterior or posterior capsules, 3 pieces IOL was preferred. When ECCE technique was chosen, single piece polymethyl methacrylate IOL was inserted.

Intervention type: PROCEDURE
Intervention: Cataract Surgery
Description: Cataract surgery was performed by using phacoemulsification technique, routinely. But other techniques for instance extra or intracapsular cataract extraction (ECCE, ICCE) techniques were performed when needed. Phacoemulsification technique was performed by 2 experienced surgeon (G.A. and E.C.) under topical anesthesia, thorough limbal incision. Foldable single piece hydrophobic acrylic intraocular lens (IOL) was inserted in the bag. In the presence of complications related to anterior or posterior capsules, 3 pieces IOL was preferred. When ECCE technique was chosen, single piece polymethyl methacrylate IOL was inserted.
Study: NCT01097239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonablate 500 (High Intensity Focused Ultrasound (HIFU))
Description: High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
Study: NCT00928746

Intervention type: DEVICE
Group type: OTHER
Intervention: Ipratropium bromide
Study: NCT01674712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Combination of Fenofibrate/simvastatin 145/20 mg
Description: Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg
Description: Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 145 mg
Description: Fenofibrate, tablet, 145 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Combination of Fenofibrate/simvastatin 145/40 mg
Description: Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40 mg
Description: simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
Study: NCT04460677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Support Plan
Description: The Emotional Support Plan (ESP) is designed to help adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Support Plan
Description: The Emotional Support Plan (ESP) is designed to help adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Monitoring
Description: The daily monitoring will remind participants 4x/day to report on their mood, distress, etc. and use their ESP if needed.
Study: NCT03302000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Visual Stimulation
Description: Early visual stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: standard care

Intervention type: OTHER
Group type: OTHER
Intervention: standard care
Description: standard care
Study: NCT01810237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran.
Description: Dabigatran will be used instead of LMWH for anticoagulation bridging.
Study: NCT02323633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Braingear Brainbuds Pulsed Current stimulation device
Description: Transcranial Pulsed Current stimulation (tPCS) at random noise oscillating frequencies for a duration of 20 minutues

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No transcranial Pulsed Current Stimulation (tPCS)
Study: NCT01782079

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. brevis
Study: NCT01284062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anrukinzumab
Description: 200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anrukinzumab
Description: 200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anrukinzumab
Description: 200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
Study: NCT04624490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xe129
Description: During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.
Study: NCT02690779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: 2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Routine Care Instructions
Description: patients will follow routine care and instructions
Study: NCT06465888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: egg whites
Description: Participants will eat four egg whites daily for the 4-week study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole eggs
Description: Participants will eat two eggs daily for the 4-week study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 eggs
Description: Participants will eat two Christopher Farms omega-3 fortified eggs daily for the 4-week study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: egg yolk
Description: Participants will eat four egg yolks daily for the 4-week study
Study: NCT04307082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Ibrexafungerp
Description: Radio-labeled Ibrexafungerp, single dose.
Study: NCT04417101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb
Description: The participants will be instructed to take their JBT and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
Study: NCT04113668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diflunisal
Description: Specified Dose on Specified Days
Study: NCT01207232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning Prompt
Description: A prompt to write down a planned date (or date and time) for getting a flu shot

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning Prompt
Description: A prompt to write down a planned date (or date and time) for getting a flu shot

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: A basic reminder mailing prompted each subject to get their flu shot.
Study: NCT00711256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sunscreen MATAS sunlotion SPF 8

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB light
Description: duration 4 times 1 minute radiation on the trunk.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB light
Description: duration 4 times 1 minute radiation on the trunk.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB light
Description: duration 4 times 1 minute radiation on the trunk.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB light
Description: duration 4 times 1 minute radiation on the trunk.
Study: NCT02390817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Administration of Sugammadex

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine
Description: Administration of Neostigmine
Study: NCT00849654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.~In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days.
Study: NCT00056862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 90 mcg/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: 180 mcg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 800 mg/day
Study: NCT03519958

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma-tissue testing
Description: EGFR T790M mutation plasma-tissue testing in NSCLC patients who progressed on previous EGFR TKI
Study: NCT03749603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIBAY Meter
Description: fluorescence probe will be applied for 3-5 minutes onto the wet vermillion of the lower lip.
Study: NCT00435474

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound treatment
Description: wound treatment (silver product, alginate and foam dressing)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound treatment
Description: wound treatment (honey product, alginate and foam dressing)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psycho-social support
Description: psycho-social support (based on the structure in cognitive therapy)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psycho-social support
Description: psycho-social support (based on the structure in cognitive therapy)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: relaxation therapy
Description: relaxation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: relaxation therapy
Description: relaxation therapy
Study: NCT04562194

Intervention type: DEVICE
Group type: OTHER
Intervention: NeVa Stent Retriever
Description: mechanical neurothrombectomy
Study: NCT02900469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denosumab
Description: denosumab: 120 mg subcutaneous injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery: approximately 2-4 weeks after dosing of denosumab
Study: NCT01372410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 125 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 62.5 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 31.25 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 15.6 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 31.25 mcg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 15.6 mcg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: 18 mcg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once or twice daily
Study: NCT00146679

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Telephone counseling (TC)
Description: Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided through telephone sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Intervention by Group (SG)
Description: Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided in 4 group sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care provided by providers
Study: NCT02297360

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Viviscal Extra-Strength Supplement
Description: The key ingredient of Viviscal Extra-Strength Supplement is AminoMar C™ marine complex, Equisetum arvense sp. (horsetail), containing a naturally occurring form of silica), Malpighia glabra (acerola cherry) which contains Vitamin C, Biotin and Zinc. The AminoMar C™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
Study: NCT02929797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8+NKG2D+ AKT Cell
Description: AKT: CD8+NKG2D+ AKT cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine
Study: NCT03876990

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Description: Quick adaptation of antibiotic treatment according to the species identified and to the results of the resistance markers present in the multiplex PCR

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Current strategy alone
Description: Identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
Study: NCT00859950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
Study: NCT01243697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desogestrel
Description: Tablets of 75 µg, once daily during 112 days
Study: NCT03141554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Betadine® PVP-I based mouth wash and gargle,
Description: 1% Betadine® PVP-I based mouth wash and gargle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Betadine® PVP-I based mouth wash and gargle,
Description: 1% Betadine® PVP-I based mouth wash and gargle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Betadine® PVP-I based mouth wash and gargle,
Description: 1% Betadine® PVP-I based mouth wash and gargle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Description: 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Description: 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
Description: 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline gargle
Description: Normal saline gargle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline gargle
Description: Normal saline gargle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline gargle
Description: Normal saline gargle
Study: NCT01589354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block
Description: An interscalene block will be performed pre-operatively using ultrasound guidance and the peripheral nerve stimulator (with the patient awake) using 20 ml of 0.375% Ropivacaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular Ropivacaine injection
Description: The procedure will be done by the surgeon at the end of the operation, with an intra-articular injection of 20 ml 0.75% Ropivacaine through the arthroscopic cannula after closure of the anterior wound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided technique
Description: The block will be performed under U/S guidance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20ml of 0.375% Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20ml of 0.75% Ropivacaine injected by the surgeon at the end of the procedure
Study: NCT01993446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRM02

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT02183285

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pharmaton PHL 00747 soft gelatine capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pharmaton PHL 00747 film-coated tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo film-coated tablets (fct)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo film-coated tablets (fct)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo soft gelatine capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft gelatine capsules
Study: NCT02629289

Intervention type: DRUG
Group type: OTHER
Intervention: HSP-130

Intervention type: DRUG
Group type: OTHER
Intervention: US-approved Neulasta

Intervention type: DRUG
Group type: OTHER
Intervention: EU-approved Neulasta
Study: NCT02729389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Social Status Condition
Description: Participants will be provided with a high degree of privilege in a game of Monopoly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Social Status Condition
Description: Participants will be provided with a low degree of privilege in a game of Monopoly.
Study: NCT02623374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-help CBT intervention (SHCBT)
Description: See 'Arms' section
Study: NCT03693456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conjunctival Allergen Challenge
Description: Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conjunctival Allergen Challenge
Description: Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conjunctival Allergen Challenge
Description: Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.
Study: NCT01303263

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational Intervention
Description: 45-minute teaching session on healthcare costs, in which each resident reviewed an itemized hospital bill for a patient he/she had cared for, followed by an open-ended discussion about reducing unnecessary costs.
Study: NCT00472329

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: fludarabine

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: TBI
Study: NCT02129920

Intervention type: OTHER
Intervention: This is an observational study
Study: NCT00780754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride
Description: 0.5mg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prostate biopsy
Description: prostate biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prostate biopsy
Description: prostate biopsy
Study: NCT04069351

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-calorie mass gainer supplement
Description: A high-calorie mass gainer supplement will be provided to all participants to promote weight gain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: All participants will complete a 6-week supervised resistance training program.
Study: NCT03283280

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ever X Posterior
Description: Resin composite restoration can be made as a direct onlay

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ever X Posterior
Description: Resin composite restoration can be made as a direct onlay
Study: NCT02652650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol
Description: Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone
Description: Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.